everyone. welcome, and Roger, you, Thank
and to quarterly Aytu the the achieving changes 'XX of positive first in adjusted of excited revenue. results extremely ever I'm share include record for trajectory the is the transformational positive EBITDA of with to company's Clearly, and years us EBITDA adjusted financial quarter come. positively you today, which first fiscal quarter
by was experienced Rx press today's driven growth XX% through to continuing increase XX% novel of affordable products ago performances due which to a the Rx and patient segments. a our to an outlined access net and The in segment the As Health program. salesforce million, Consumer quarter is and our our release the the access was gain year strong both of our compared RxConnect quarterly $XX.X revenues our record sales in to enables continuing Rx of execution proprietary with of business. RxConnect free products force Aytu's prescription cornerstone predictable hassle along and patient revenue leverage we're Aytu
to GAAP segment positive million, can adjusted had the the Further EBITDA. second which now understanding overhead EBITDA adjusted corporate the is This see positive this earlier you Rx EBITDA press $X.X that quarter Please we all reconciliation consecutive in our burden that segment has the of Rx note afternoon. had the adjusted release in G&A virtually to net segment. is in issued income
patient witnessed our and As strides I is September centric making significant that our mentioned with again salesforce once the messaging. in physicians And momentum we in back first quarter.
experiencing ADHD growth in the additional are both markets from pediatrics. within segment of the we tailwinds Additionally, a into dive and serve in drivers Rx moment. I'll our we in
and quarter we first Health XXX,XXX. in to just segment our EBITDA the Consumer reduced to posted strong growth revenue last side, compared the XX% On adjusted year's loss
will Importantly, the brand of launch moment. we coming in up saw solid this a OTC medicines within and which fiscal the growth Consumer Health, additional family year drivers I here including more C'rcle about talk
and first to important to company the commercial of we last improvement dramatic shift company achieving first quarter, million negative for our announced EBITDA the year's adjusted was the sure. $X.X On $X.X quarter a compared told aimed in at the accelerating to strategy an positive October growth All million during profitability. be business XX, a
development indefinite Syndrome Enzastaurin vascular or of VEDS. the our Ehlers-Danlos of suspension programs, noted ARXXX clinical we treatment including for result, a As the
allow path XX the our to maximizing synergies us million expected with revenue, our The save profitability. positive is growing we positive on expenses, will costs adjusted and trajectory company over down to center as and to EBITDA efforts to projected we accelerate continue study driving the suspension all in serve have which future of
With clearer. We markedly our program suspension beds our in path EBITDA quarter of hand, now do generated the has a all clinical adjusted disappointment that first funding with is take lightly. with cash the that and partnering. we understand to at community, flow become development to time expectation that revisit the ARXXX program or not clinical internally of We the intend future through appropriate the development
strongly commercial flow the to it the capital markets. accelerating focus is generating in reliance to minimize stakeholders our of interest us today's In efforts we and economic the on our businesses environment growth for on believe best of cash all positive the
want avoid we to our And and bottom operations diluted just avoid we believe the taken steps large of is that. positioned do our that trajectory given are and financing. commercial with the cash we highly a The line position, to coupled we've
more, with Rx beginning Let's segment. commercial bit the a our dive into business
operate with acquisition delivery formulated by release Rx the and our we areas, in microparticle within primarily technology patient friendly that Therapeutics. of reminder, portfolio the The acquired portfolio disintegrating year a segment, ADHD last Neos proprietary release, platform stimulant product tablets in therapeutic We orally March Neos. As developed the modified medications in utilize drug of pediatrics. ADHD two extended includes
and prescriptions ADHD position only Cotempla respectively, FDA growing the methylphenidate nearly extended release a approved generating are for and million XX finding the this are in ODTs stimulant United the within and ADHD, of category, treatment and a category large Adzenys amphetamine they annually XR-ODT XR-ODT States. first and well-earned
as seeing the an increase of to growth in million strong contributing numerous will shortages more in First, $XX.X which year The to the of see Further ago. quarter in manufacturers growth products drivers we but be things and this key of generic the reporting the amphetamine, largely to ongoing across delays, to contributed prescribed category. manufacturing first revenues, market continue most Mark Adderall diagnoses. attributable come hit overall there an supply molecule to in XXXX we ADHD the XX% numbers pandemic a compared in to increase on out are can XR three ADHD Board the the growth are
generics associated these the with prescribers Adzenys robust has confusion we've Adderall the partners remains XR concern among disruptions supply patients and XR-ODT and our supply medications, to the uninterrupted. clinician and While clear made that taking it ADHD caused
in for foreseeable XR market are that some quarters we mind for future. enable see Adzenys expect is Keep as could that supply approved to mindshare. bioequivalent so a the as the meaningful supply XR I tailwinds the coming continue intermittently expected will to continued Adzenys in to disruption gain disruptions Adderall Adzenys and
highly our getting better is key making force execution and young to overall The that messaging. ADHD more motivated the driver sales improvement has second growth strides and with and sales, consistent and of been energized targeting
one following populated of sales We of professionals with care that have mostly the the and under favor who they're industry cost health motivated excited with much hungry. and legs profile sales traction in great to the field, we're force new getting turnover lower a their team them They're are this upside of is providers. the about in getting high
And finally, the RxConnect. leverage we're gaining through Aytu
more continue we've country, Based improved we all prescriptions network in nearly drives cultivate our on in pharmacies increase growth Xx per reduction Aytu prescription shown a pharmacies, the Rx, key markets in across data net and a of some in refills. RxConnect in As products. co-payments X,XXX than channel margin of points, out for distribution recent patient XX% Aytu's pocket prescription a compared our results non-network to that XX% roughly by improvement filled roughly to our
products future inception the The which been Aytu with platform of the truly since leveraged purpose patients, the has does program. providers, for the RxConnect included value already Aytu be Aytu may healthcare Karbinal platform. them for legacy bring drive in can and the Aytu and in for demonstrated more Further, RxConnect growth current products our we into products portfolio. the of new we significant since our Tri-Vi-Flor and Poly-Vi-Flor, We've
to transfers both One the profitability to to on improvement to tech of accelerate the Adzenys keys the further bottom line is Cotempla. of and plan continued path
meaningful This we calendar As margin to ADHD will mandated outsourcing further September, improve everything products gross manufacturer, in a and of P&L. FDA the of achieved improve back bioequivalence ADHD the by well already change finalized if our with product producing is more, step the our our reported stands and to studies contract XX% other improved It or XXXX. profit that having conduct work. CMO process the including the underway is in goal
On containing combinations includes lines multivitamin side, Poly-Vi-Flor with fluoride portfolio of fluoride our fluoride prescription the and vitamins various product pediatric based Tri-Vi-Flor formulations deficiency. in two and and complimentary children infants for
for older. based numerous over and patients branded two and clinical pediatric We offer suspension also and and serve large and competitive These market products. conditions allergic extended established released the Karbinal patient benefits generic years to ER indicated carbinoxamine antihistamine features markets products distinct treat
million third key pediatric million payor annualized that solid and Again, salesforce in revenues a quarter for the some which revenues XX% During here on growth growing leveraging execution, a rate. $X.X from environment, products. lines first geographies, plus provided prescription and with second the and particularly we tailwind drivers has the to various the portfolio $XX are our for multivitamins run Aytu of RxConnect, revenue achieved putting
should Since age, RxConnect, no stated whose drinking brands. fluoride grown and risk for we Association or contains primary months decay added PVF those high XX for prescriptions are to growth low truly years has have Dental to supplements demonstrate tooth American be of significantly and The to that TVF we continue six at children fluoride. who prescribed remarkable with and water
in fact New major While lack fluoridated, majority of U.S. much and the is geographic it. some York's Jersey, drinking water including New Long Island of areas
rely in recommended four support We supply of receive business. the coupled in areas will with that the or risks understanding municipalities increased do that that the the on we in the of continued fluoride in children documented ADA, see fluoridate this not well with live well water through rural one fluoridation. water growth not from Approximately think levels American do
fluoride serve growth We're both existing we and opportunities multivitamin for basis from Tri-Vi-Flor line the And to which expansion and fluoride Poly-Vi-Flor expect new additional continually as need as sales. of geographies will look supplementation. areas we grow the evaluating in to across
achieving traction Overall, about in we are Rx the our segment. feel confident we
million we the With gross cost EBITDA expect positive reductions continued quarter growth positive and going XX% revenue forward. experienced growth in adjusted place, As EBITDA. improvement generated we first margin measures a mentioned, and $X.X in in quarters
Let's transition segment. our now Health to Consumer
year XXXX Health of Consumer $X an the net XX% first quarter million for sales were of a segment, During over QX ago. increase
our national management, segment, value with branded with not competing core Health and products categories such Consumer product those digestive health, For familiar allergy, higher on large price hair loss, based listeners is competing as brands. focus in all our diabetes,
or value by At to consumers consumers a a for these anywhere and on All save can, great they are believe intended products conditions used have continued chronic address be we brands basis. opportunity a growth. for are looking recurring time when to opportunities largely regular
reordering product building easy monthly As such, a allows for and value the brands for subscription annuity ongoing and used these offer by for which and customers we program use company. strong
directly sell platforms, We e-commerce the in branded to including platform. consumers websites through Amazon
products the or marketing mail, Additionally, to through direct proprietary focuses segment to business which centers call and with directly on sales homes. platform, primarily sells purchase shipment through consumer reply, directly allowing our their consumers through
the medicines 'XX pivot value within our through to to decision of efforts in fiscal of was with website. Amazon visibility digit that OTC we growth channel on with made online Recall in launches. improving more efficient double channel to growth primarily on solid the focus product and The the higher the in a quarter Consumer new margin strategic sales our due primary Amazon our our Health coupled a
the of focus business, to simply mail focus While going be profit growth to has that was forward we scale online OTC will brands generate these on clear it business fruit driving shift the consistent to business. our and driven e-commerce consumer on could continuing more this the The direct have with lay to side. borne opportunity OTC us and primary by the medicines this channel and revenue
while use single brand a margins. for shop seeking the over line stop addressing all build through out we of based equity, everyday counter common products are higher and C'rcle a ordering we family family range one family brand collective common brand more drive in OTC will create branded value of establishing medicines conditions value calendar build ultimately are to and Health. a an will yielding to overall higher brands C'rcle addressing out recognized annuity showcasing planning believe represent of planning customer Importantly, We brand repeat further a conditions. we OTC a value common roll value the which 'XX medicines family
approach out and build family as rebrand the the to As part expect we the new integrate launch. of C'rcle these we to products of products existing as C'rcle, more well all as launch and C'rcle launch follow into brand
segment to Health significant a seeing cash. Consumer segment we a marking improvement EBITDA very close to posted quarter, ago, this now in the During $XXX,XXX getting compared adjusted negative of a that is negative a $XXX,XXX generating year
In indefinite on of long members focus gross connection our driving the changes executive the a of aligning leadership driving with expenses, of clinical to program, and profitability. leadership team at and strategic growth, suspension further the we consolidating commercial our decision margins revenue series skills our to announced business development the improving goals of aimed term
Jarrett Officer dynamic poised since created brands to to experience and of Consumer appointed company the build Rx Co-Founder Co-Founded across Business newly enterprise. consumer and inception, we to Disbrow Health. high growth the at our Aytu is First, Jarrett into and centric President, Health role his take both leading Consumer a consumer Chief with segment Having
expansion, of business rebranding launches, growing Consumer business, Health new medicines continued to has Jarrett think for We has flow rollout implementing the I and bode for the segment C'rcle OTC of the for profitability and transition this an this growth plans specifically the in quarters. product Health and begun well and as discussed. just exciting cash should vision segment part the continued coming
at Topher newly role promotion Therapeutics centric his to executive we to the Co-Founder Operating Topher's Operating him smaller and biotech global Rumpus leadership Chief pharma of re-established business units pediatric companies of Chief large Brooke with as well-suited makes the both of Additionally, the coupled announced orientation especially step into Officer. biotech entrepreneurial Officer.
the we production and manufacturing will Cotempla corporate increase and move affairs key Adzenys also development the contract Topher manufacturer. regulatory forward. margins of lead a outsourcing to aspects be scientific transition for affairs, global medical business prescription and COO, by Grand As He and going will significantly quality of to responsible as strategy Prairie and and
efficiencies was Finally, Consumer strategic Executive of Ryan's coupled dovetails oversee Selhorn as Optimization. financial Consumer projects Finance the we the and in and promoted in President, the revised plans. Vice and a created cost accounting He organizational and improvement the in and company ongoing with public numerous for to previously expertise Vice role Health and his consolidation internal in our savings spearheading President, Ryan both pharma while into significant Senior processes, Ryan also organization. to Finance accounting, will finance and lead prior of experience Operations Business CFO perfectly throughout functions expected drive public and the streamlining segment. Health, newly
as Rx overseeing year-over-year. commercial operations Pyszczymuka Greg will all aspects commercial a upgrade repeat I'll grown significant which streamlining leadership and in Chief Officer, Greg's a forward enthusiasm this of these remain the role in Commercial our under the the We've business, has trajectory of our talent renewed his leadership, in portfolio. of his XX% Rx their company's focus. in and growth experienced strong continuing thankful look across to growth, for phase growth and team and support next leaders I'm this of and Greg
entire truly rallied EBITDA. to and organization. around which the company positive ever with Before of the to proud Mark, a incredibly am turn great team just I first led has The operating build revenue how over opportunity it record quarter quarterly say let to I our me adjusted has
our of are activities have and future the the the ability manufacturing cutting Neos including of enhance know growth outsource cash both becoming stands there of be segments funding the trends self-sustaining even we to without that and way the and to elimination driving sales R&D there in this that Importantly, a any any execute direction the tied performance We such self-sustaining synergies, of cost further, additional as in saying change continued we dramatically flows merger near post variations can as but implementation in drivers expenses, forward that goal are our to heading on for quarter the the it's to It clear think term. in basis. reasons goes about go single being multitude on right us pipeline.
it overview, numbers. the Oki color our that turn some me With to Mark to additional let Mark? add over CFO, to
